Histone deacetylase inhibitors: multifunctional anticancer agents.
about
Clinical use and applications of histone deacetylase inhibitors in multiple myelomaHistone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytesEfficient cell migration requires global chromatin condensation.VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival.A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsSpecific activity of class II histone deacetylases in human breast cancer cellsThe possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical studySuppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulatorsValproic acid induces Notch1 signaling in small cell lung cancer cellsNF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement.A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Effects of endostatin and a new drug terpestacin against human neuroblastoma xenograft and cell lines.Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).Triple-negative breast cancer: new perspectives for targeted therapies.Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brainSynthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilanyloxy) decanoic acid, a Precursor to the Unusual Amino Acid Residue of the Anticancer Agent Microsporin B.Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.Relevant molecular markers and targets.Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway.Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.Enhancing the anti-angiogenic action of histone deacetylase inhibitors.Metastasis: recent discoveries and novel treatment strategies.Epigenetics, TET proteins, and hypoxia in epithelial-mesenchymal transition and tumorigenesisNovel therapies for meningiomas.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis.Genome-wide association study identifies possible genetic risk factors for colorectal adenomas.Effect of a chemical chaperone, tauroursodeoxycholic acid, on HDM-induced allergic airway disease.HDAC inhibitors in kidney development and disease.Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineageThrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.
P2860
Q26745930-29A2E7FE-80A8-4D24-8019-1017EF9A7A0FQ27324527-91FAFEE8-BA21-4F09-9EF9-871FFA9C9A3FQ30494900-CFCCEBC9-3F3F-4333-A31E-1AB67161F88CQ33321264-39B65C54-48E9-4BF7-B55A-9B107AC9655BQ33384180-3C6FFF9C-186C-4501-AD42-48F0ED678F0EQ33402040-66622EE8-DACE-49C0-840B-64DCF5A0AE1CQ33606021-AE44674B-0109-436E-9CE8-270992AE0EC8Q33712267-90A899F4-4EFC-4CD7-8A35-BF4CFB1E28A9Q33852611-244C6179-580F-4500-AAB2-A6838BC91CEFQ33976203-EE1D26E3-49AB-4FC2-B89C-60394AEC89A9Q34033879-64FC31CA-5D9E-499D-B81A-193BB94F6C52Q34099365-A51D624F-3023-42BA-A405-32BE854ABD21Q34101036-DFA5D5A0-DC25-4766-BF9A-3C879424C941Q34224278-7464A95A-5F21-4DF5-8130-B211C3C838D7Q34373673-36CF49E5-6AFD-4858-B73D-EF9209A603F2Q34399444-E7452C22-0AFB-489C-9130-F0A5AB6A897CQ34417159-D69071DC-E672-42F5-8A51-97DFC1ABCA6AQ34725589-A203FC6C-5B54-4729-A397-E9B9E3865404Q35001758-FCD2609F-75D2-49E2-80E4-1E467423D43EQ35198599-F16333A7-4784-4934-9A02-2BDB96B17D5DQ35258648-0EE5C2ED-ECD0-420B-8181-A7EEE414BFAFQ35742395-5F717D99-91CC-45A9-98F1-C25E93054426Q35791117-2E9BBE36-BF10-4DE9-955A-CCBF4B839D1CQ35857775-D2138733-1308-44AF-A242-F34B7E2B6534Q35915103-8734BD15-65DC-492D-9CD7-2A6BE831C919Q36245380-DFF6F881-C831-4C0F-8EF7-A3E256A866D5Q36257402-C8002738-FC14-4789-99F5-7E68BDB17C67Q36276954-D0CEB26B-37AE-44C0-A5BF-3648321087F3Q36325361-039C04A8-F1DC-44C2-86E4-3763C9A47F81Q36407511-B43B1A1B-9E0E-4EBE-A2A5-DD020F08E7FAQ36573115-AB2B1CF9-F89B-47DE-BB51-FF39528B5AB2Q36641500-9A07BA6E-95E3-48C8-B9A4-7B65FF9D8519Q36801625-A7AEE411-5993-4454-B06D-18ED0EB4991FQ36985083-2C43C3CE-11B0-426B-9677-3F659C2F238EQ37017072-3466193F-4B2A-4699-B118-9883CCBC5D2AQ37027423-27E9235E-E036-42A9-94E7-7470E64A2E33Q37071741-43D4BD0B-F571-41AF-BB1F-3E4140B1D0ACQ37115414-022CAF0C-C6B6-48D8-A9ED-606B3157AA2BQ37167249-F74E2398-9CF2-4BC8-826D-EBCE1E2FD43EQ37294120-6C070759-3529-4EBD-8CE5-6876BB52089D
P2860
Histone deacetylase inhibitors: multifunctional anticancer agents.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Histone deacetylase inhibitors: multifunctional anticancer agents.
@ast
Histone deacetylase inhibitors: multifunctional anticancer agents.
@en
type
label
Histone deacetylase inhibitors: multifunctional anticancer agents.
@ast
Histone deacetylase inhibitors: multifunctional anticancer agents.
@en
prefLabel
Histone deacetylase inhibitors: multifunctional anticancer agents.
@ast
Histone deacetylase inhibitors: multifunctional anticancer agents.
@en
P2093
P1476
Histone deacetylase inhibitors: multifunctional anticancer agents
@en
P2093
Andrew Tee
Glenn M Marshall
Selena Kuljaca
P304
P356
10.1016/J.CTRV.2005.12.006
P50
P577
2006-03-03T00:00:00Z